{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:28:02Z","timestamp":1792726082191,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","award":["1U01FD005259-01"],"award-info":[{"award-number":["1U01FD005259-01"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["UM1TR004402"],"award-info":[{"award-number":["UM1TR004402"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.xphs.2024.09.025","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:25:33Z","timestamp":1729005933000},"page":"313-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Changes in drug crystallinity in a commercial tacrolimus amorphous formulation result in variable pharmacokinetics"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4568-6021","authenticated-orcid":false,"given":"Lynne S.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj S.","family":"Trasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4789-3032","authenticated-orcid":false,"given":"Hitesh S.","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minori","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanglin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjida","family":"Mahjabeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairui (Kevin)","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali K.","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond E.","family":"Galinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2024.09.025_bib0001","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.xphs.2018.11.003","article-title":"Enabling an HCV treatment revolution and the frontiers of solid solution formulation","volume":"108","author":"McKelvey","year":"2019","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.025_bib0002","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jps.23031","article-title":"Assessing the performance of amorphous solid dispersions","volume":"101","author":"Newman","year":"2012","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2024.09.025_bib0003","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/jps.24541","article-title":"Amorphous solid dispersions: utilization and challenges in drug discovery and development","volume":"104","author":"He","year":"2015","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.025_bib0004","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.09.025_bib0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2016.03.006","article-title":"Physical chemistry of supersaturated solutions and implications for oral absorption","volume":"101","author":"Taylor","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.025_bib0006","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/17425247.2017.1230099","article-title":"Supersaturation and crystallization: non-equilibrium dynamics of amorphous solid dispersions for oral drug delivery","volume":"14","author":"Kawakami","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.025_bib0007","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1021\/acs.molpharmaceut.9b00455","article-title":"Assessing the impact of endogenously derived crystalline drug on the in vivo performance of amorphous formulations","volume":"16","author":"Purohit","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.xphs.2024.09.025_bib0008","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2018.11.003","article-title":"Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport","volume":"292","author":"Wilson","year":"2018","journal-title":"J Controll Release"},{"key":"10.1016\/j.xphs.2024.09.025_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120005","article-title":"Elucidating the effect of crystallization on drug release from amorphous solid dispersions in soluble and insoluble carriers","volume":"591","author":"Ojo","year":"2020","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.025_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1208\/s12248-021-00598-6","article-title":"Amorphous solid dispersions containing residual crystallinity: competition between dissolution and matrix crystallization","volume":"23","author":"Moseson","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2024.09.025_bib0011","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1007\/s11095-012-0695-7","article-title":"Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications","volume":"29","author":"Qian","year":"2012","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.025_bib0012","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10717544.2019.1704940","article-title":"Mechanisms of increased bioavailability through amorphous solid dispersions: a review","volume":"27","author":"Schittny","year":"2020","journal-title":"Drug Deliv"},{"key":"10.1016\/j.xphs.2024.09.025_bib0013","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejpb.2016.02.007","article-title":"Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib: PVP amorphous solid dispersions","volume":"101","author":"Knopp","year":"2016","journal-title":"Eur J Pharmaceut Biopharmaceut"},{"issue":"5","key":"10.1016\/j.xphs.2024.09.025_bib0014","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1021\/acs.molpharmaceut.8b00043","article-title":"Manufacturing amorphous solid dispersions with a tailored amount of crystallized API for biopharmaceutical testing","volume":"15","author":"Theil","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2024.09.025_bib0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejpb.2018.07.005","article-title":"Effect of amorphous phase separation and crystallization on the in vitro and in vivo performance of an amorphous solid dispersion","volume":"130","author":"Knopp","year":"2018","journal-title":"Eur J Pharmaceut Biopharmaceut"},{"key":"10.1016\/j.xphs.2024.09.025_bib0016","article-title":"Trends in amorphous solid dispersion drug products approved by the US Food and Drug Administration between 2012 and 2023","author":"Moseson","year":"2024","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.xphs.2024.09.025_bib0017","first-page":"17","article-title":"The oral dosage form of FK-506","volume":"19","author":"Honbo","year":"1987","journal-title":"Transplantation Proc"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2024.09.025_bib0018","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2003.07.010","article-title":"Establishment of new preparation method for solid dispersion formulation of tacrolimus","volume":"267","author":"Yamashita","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2024.09.025_bib0019","first-page":"1","article-title":"Evaluation of the crystallization tendency of commercially available amorphous tacrolimus formulations exposed to different stress conditions","author":"Trasi","year":"2017","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.xphs.2024.09.025_bib0020","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.xphs.2017.12.024","article-title":"Investigating the impact of drug crystallinity in amorphous tacrolimus capsules on pharmacokinetics and bioequivalence using discriminatory in vitro dissolution testing and physiologically based pharmacokinetic modeling and simulation","volume":"107","author":"Purohit","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.09.025_bib0021","unstructured":"Tacrolimus Capsules. The United States Pharmacopoeia; 2013."},{"issue":"1","key":"10.1016\/j.xphs.2024.09.025_bib0022","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.xphs.2016.09.016","article-title":"Non-sink dissolution behavior and solubility limit of commercial tacrolimus amorphous formulations","volume":"106","author":"Trasi","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.09.025_bib0023","unstructured":"Astellas Pharma US IN, IL 60062. Highlights of prescribing information, PROGRAF (tacrolimus) capsules, for oral use. Revised July 2021."},{"issue":"1","key":"10.1016\/j.xphs.2024.09.025_bib0024","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijpharm.2017.10.051","article-title":"Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery \u2013 an update","volume":"535","author":"Jermain","year":"2018","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2024.09.025_bib0025","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2024.09.025_bib0026","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2016.03.009","article-title":"Navigating the human gastrointestinal tract for oral drug delivery: uncharted waters and new frontiers","volume":"101","author":"Koziolek","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10.1016\/j.xphs.2024.09.025_bib0027","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/jps.23826","article-title":"Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs","volume":"103","author":"Raina","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.09.025_bib0028","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1023\/A:1010948630296","article-title":"Supersaturation: enhancement of skin penetration and permeation of a lipophilic drug","volume":"18","author":"Moser","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.xphs.2024.09.025_bib0029","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.3c00526","article-title":"Crystallinity: a complex critical quality attribute of amorphous solid dispersions","author":"Moseson","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.xphs.2024.09.025_bib0030","series-title":"Crystallization","author":"Mullin","year":"2001"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.025_bib0031","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jps.10041","article-title":"Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats","volume":"91","author":"Tamura","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.09.025_bib0032","unstructured":"Public Assessment Report of the Medicines Evaluation Board of the Netherlands. Tacrolimus Intas 5 mg capsules. United Kingdom: hard Intas Pharmaceuticals Limited. EU-procedure number: NL\/H\/1333\/004\/DC"},{"key":"10.1016\/j.xphs.2024.09.025_bib0033","unstructured":"Food and Drug Administration. Draft guidance on tacrolimus. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Tacrolimus_cap_50708_RV12-12.pdf. Accessed 08\/02\/2024."},{"key":"10.1016\/j.xphs.2024.09.025_bib0034","unstructured":"Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an abbreviated new drug application. Available at:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug. Accessed 08\/02\/2024."},{"key":"10.1016\/j.xphs.2024.09.025_bib0035","unstructured":"Bioequivalence Study of Tacrolimus in Healthy Volunteers. ClinicalTrials.gov ID NCT04725682. 09\/21\/2023 ed.; 2023."},{"key":"10.1016\/j.xphs.2024.09.025_bib0036","unstructured":"FDA is changing the therapeutic equivalence rating for Accord Healthcare Inc.\u2019s generics of Prograf (tacrolimus) oral capsules Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-changing-therapeutic-equivalence-rating-accord-healthcare-incs-generics-prograf-tacrolimus-oral. Accessed 11\/20\/2023."}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T01:35:50Z","timestamp":1734744950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924004337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0022354924004337"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.025","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in drug crystallinity in a commercial tacrolimus amorphous formulation result in variable pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}